אביליפיי 15 מ"ג
Country: Iżrael
Lingwa: Ebrajk
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
ARIPIPRAZOLE 15 MG
Disponibbli minn:
BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED
Kodiċi ATC:
N05AX12
Għamla farmaċewtika:
TABLETS
Rotta amministrattiva:
PER OS
Manifatturat minn:
BRISTOL-MYERS SQUIBB S.R.L, ITALY
Grupp terapewtiku:
ARIPIPRAZOLE
Indikazzjonijiet terapewtiċi:
Abilify is indicated for the treatment of schizophrenia. And for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
Data ta 'l-awtorizzazzjoni:
2010-02-01
